AnaptysBio, Inc. (ANAB) Stock AnalysisANABAnaptysBio, Inc.

AnaptysBio, Inc. is a royalty management company. The Company manages the financial collaborations for Jemperli with GlaxoSmithKline (GSK) and imsidolimab with Vanda Pharmaceuticals Inc. (Vanda). The Company's financial collaboration with GSK is focused upon the development and commercialization of Anaptys-discovered Jemperli (dostarlimab), a PD-1 antagonist, approved for endometrial cancer and dMMR pan tumors, and is being studied in rectal cancer, colon cancer and head and neck squamous cell carcinoma. The Company's financial collaboration with Vanda is focused upon the development and commercialization of Anaptys-discovered imsidolimab, an IL-36R antagonist, which is being developed for generalized pustular psoriasis (GPP). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

AnaptysBio Inc is currently at a price of $56.28 with a forward P/E of 0, indicating potential for future earnings but also uncertainty. The RSI is at 36.949, suggesting it is nearing oversold conditions, which could indicate a buying opportunity. However, the company reported a disappointing Q1 EPS of -1.84, missing expectations significantly, which raises concerns about its profitability and future cash flow. The main risk is the ongoing litigation with Tesaro, which could impact its market position and revenue from the Jemperli product, currently approved in over 35 countries.

8 analysts cover ANAB: 8 rate it Buy, 0 Hold and 0 Sell. The average price target is 74.13.